vorasidenib
servier
['indigo']
plenary: indigo trial waltz around the tca cycle diffuse, g2 idh1/2mt gliomas after maximal safe resection given vorasidinib vs watchful waiting: mpfs 27.7mo vs 11.1mo, hr: 0.39.
new standard of care option
#asco23 
Medical Oncologist. Chief of Hem/Onc, PD of hem/onc fellowship, Dr Peter White Endowed Professor, & Associate Professor at The University of Toledo.